January 2023 Issue: Apellis Pharmaceuticals (SYM: APLS)
- Dylan Jovine
- Friday, January 13, 2023
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population).
As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
July 2022 Issue: ImmunoGen, Inc. (NAS: IMGN)
- Dylan Jovine
- Friday, July 15, 2022
For 40 years, ImmunoGen has been targeting a better life for people with cancer, as they believe it’s not enough to disrupt the progress of the disease, they want to keep cancer from disrupting someone's life.
January 2023 Issue: Apellis Pharmaceuticals (SYM: APLS)
- Dylan Jovine
- Friday, January 13, 2023
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population).
As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
July 2022 Issue: ImmunoGen, Inc. (NAS: IMGN)
- Dylan Jovine
- Friday, July 15, 2022
For 40 years, ImmunoGen has been targeting a better life for people with cancer, as they believe it’s not enough to disrupt the progress of the disease, they want to keep cancer from disrupting someone's life.
Categories
Recent posts
Tags
Connect with Us
Get FREE Weekly Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.